Embolischer Schlaganfall unbekannter Quelle (ESUS)

ZUSAMMENFASSUNG

ESUS (embolischer Schlaganfall unbekannter Quelle) wurde als pathogenetisches Konzept mit der Erwartung entwickelt, dass eine orale Antikoagulation wirksamer als eine Thrombozytenfunktionshemmung einen erneuten Schlaganfall verhindern kann. Zwei pivotale Phase-III-Studien (NAVIGATE ESUS, RE-SPECT ESUS) haben diese Erwartung nicht bestätigt. ESUS ist keine singuläre pathogenetische Entität. Zukünftige Konzepte müssen das berücksichtigen, um einer personalisierten Therapie den Weg zu ebnen.

• Literatur

• 1 Adams Jr. HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
• 2 Hart RG, Diener HC, Coutts SB. et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429-438
• 3 Hart RG, Catanese L, Perera KS. et al. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke 2017; 48: 867-872
• 4 European Stroke Organisation Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507
• 5 Furie KL, Kasner SE, Adams RJ. et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 227-276
• 6 Cotter PE, Martin PJ, Ring L. et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology 2013; 80: 1546-1550
• 7 Ritter MA, Kochhauser S, Duning T. et al. Occult Atrial Fibrillation in Cryptogenic Stroke: Detection by 7-Day Electrocardiogram Versus Implantable Cardiac Monitors. Stroke 2013; 44: 1449-1452
• 8 Sanna T, Diener HC, Passman RS. et al. Cryptogenic stroke and underlying atrial fibrillation. New Engl J Med 2014; 370: 2478-2486
• 9 Poli S, Diedler J, Härtig F. et al. Insertable cardiac monitors after cryptogenic stroke – a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol 2016; 23: 375-381
• 10 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. Eur Stroke J 2016; 1: 146-154
• 11 Diener HC, Easton JD, Granger CB. et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke: official journal of the International Stroke Society 2015; 10: 1309-1312
• 12 Geisler T, Poli S, Meisner C. et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke 2017; 12: 985-990
• 13 Thijs VN, Brachmann J, Morillo CA. et al. Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology 2016; 86: 261-269
• 14 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New Engl J Med 2018; 378: 2191-2201
• 15 Hankey GJ, Patel MR, Stevens SR. et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322
• 16 Verma N, Ziegler PD, Liu S. et al. Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: Insights from insertable cardiac monitors. Int J Stroke 2018 DOI: 10.1177/1747493018798554: 1747493018798554
• 17 Kasner SE, Swaminathan B, Lavados P. et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol 2018; 17: 1053-1060
• 18 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891
• 19 Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy recent – Data and ideas. Stroke 2005; 36: 1588-1593
• 20 Lip GYH, Keshishian A, Li X. et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. The ARISTOPHANES Study. Stroke 2018; 49: 2933-2944
• 21 Amarenco P, Albers GW, Denison H. et al. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. Stroke 2017; 48: 2480-2487
• 22 Ntaios G, Papavasileiou V, Lip GY. et al. Embolic Stroke of Undetermined Source and Detection of Atrial Fibrillation on Follow-Up: How Much Causality Is There?. J Stroke Cerebrovasc Dis 2016; 25: 2975-2980